US Manufacturing Growth Slips to Seven-Month Low
Health Care Equipment and Services
More
-
Genzyme said Sunday that three-year data from a mid-stage trial of its experimental multiple sclerosis drug showed it to be very effective, but patients must be monitored on a monthly basis to avoid a potentially deadly side effect.
-
A new blood test could possibly tell you if your forgetfulness is the beginning of Alzheimer's — two to six years before you might be formally diagnosed with the disease. But what are the health care coverage implications for someone who tests positive? And the employment implications as well? Would you take the test?
-
Peter Rost, who burst onto the business news landscape a few years ago as a Pfizer whistleblower and the subject of a piece on CBS' "60 Minutes", is enjoying a new career as a blogger and a reporter for Brandweek. And late yesterday he's blitzing some of his reporter contacts with this item about the apparent 180-degree change presidential politics at the world's biggest pharmaceutical company.
-
It didn't take long. Yesterday, I blogged that I'd be curious to hear what the response of doctors might be to Genentech's new crackdown on the use of Avastin instead of Lucentis for age-related macular degeneration. Today, the American Academy of Opthamology put out a press release saying the new policy "could have a significant impact on the care of patients with (AMD)."
-
Yesterday I reported that Genentech had quietly buried on its web site www.gene.com the announcement of its new crackdown against using Avastin instead of Lucentis for adult-onset blindness. From the homepage, I had counted four somewhat counterintuitive clicks to get the link to the letter detailing the new policy.
-
Shortly after writing my last blog entry on Genentech's new ranking and part of the reason for its fall being blamed on the Lucentis/Avastin eye drug controversy, I came across this news item on The Wall Street Journal's Health Blog.
-
What a week for upsets. First, the 35-game home field winning streak of my USC Trojans comes to an end at the hands of the 40-point underdog Stanford Cardinal. Then, today, Genentech's six-year reign at the top of a big industry survey is over. Boehringer Ingelheim is the new number one!
-
Late yesterday an FDA panel of outside experts unanimously recommended the agency approve Medtronic's drug-coated stent called, "Endeavor". Unlike drugs, there is no telegraphed date for an agency decision, but analysts think the FDA will approve the device by the end of the year or early next year.
-
Melanoma -- a type of skin cancer -- is the most common form of cancer. It can spread very quickly and the prognosis often is not good. The American Cancer Society estimates that nearly 60,000 new cases of melanoma will be diagnosed this year and more than 8,000 patients will die. You can find out more about it on the ACS's website.
-
As we head into the thick of earnings season some analysts are putting out their preview notes for clients. And a couple of interesting ones about the kings of biotech, Genentech and Amgen, have come into my inbox over the past couple of days. Genentech reports after the bell next Monday, October 15. And Amgen comes out, also after the bell, ten days later on the 25th.
-
This morning, the world's second biggest drug company, GlaxoSmithKline, announced that Andrew Witty will replace JP Garnier as CEO at the end of next May. It's been known for a while that Garnier would be retiring next year, and the question was who would be tapped to succeed him.
-
This morning Bear Stearns put a $700 price target on shares of Google. But that's not the only stock getting a new stratospheric price target by an analyst. Michael Shulman is not Bear Stearns--he writes a newsletter for subscribers called, "ChangeWave Biotech Investor" and he maintains a blog. And in his weekly message yesterday Shulman moved his price target on Cepheid spacer from $40 to $110.
-
Discussing leadership, motivation and career success with Jack Welch, former General Electric chairman & CEO.
-
Novartis, the newest entrant in the flu vaccine market, is trying to give its sales a shot in the arm through the use of flu-shot gift cards, and a recent study is certainly bolstering that effort.
-
Close on the heels of announcing the hiring of a Chief Talent Officer, Pfizer this morning named a new head of Global Research and Development to replace John LaMattina who had earlier said he'd be leaving the drug company. It was on LaMattina's watch that Pfizer's next potential breakout blockbuster drug, torcetrapib for cholesterol, failed in a late-stage clinical trial.
-
Pfizer put out a press release this morning announcing that it has added another office in the C-Suite. The world's biggest drug company has hired a CTO. What's a CTO, you ask?? Well, it doesn't stand for what you might guess--Chief Technology Officer. Nope, Pfizer has created the position of Chief Talent Officer.
-
This week it's 25 years since the first of seven people in Chicagoland died after taking Tylenol laced with cyanide. The scare led to new industry-standard, tamper-resistant over-the-counter drug packaging and became an enduring textbook case for corporate crisis management.
-
Everyone's favorite biotech--investors seem to either love it or hate it--was one of the presenters this morning at the UBS Global Life Sciences Conference in New York City. CEO Dr. Mitchell Gold once again did the honors. Generally speaking, biotech investors focus on milestones or key events in drug development.
-
U.S. health care could undergo its biggest revolution in decades under the proposals of presidential hopefuls trying to fix a system that has left one in seven Americans without insurance.
-
GOP Health Care Plans